The Dako PD-L1 IHC 28-8 pharmDx Interpretation Training for Melanoma is no longer available in the U.S. due to a product labeling update.

Specifically, the science from CHECKMATE 067 no longer supports utility of PD-L1 IHC 28-8 pharmDx in metastatic melanoma to guide treatment decisions for OPDIVO® alone or in combination with YERVOY®.

For more detailed information, contact your Agilent representative.

You will now be redirected to the PD-L1 IHC 28-8 pharmDx eLearning landing page for additional information.